SeaStar Medical's QUELIMMUNE Therapy Gains Key Adoption

SeaStar Medical shares are trading higher after announcing the adoption of its QUELIMMUNE therapy for critically ill pediatric patients with acute kidney injury at Texas Children’s Hospital, following its FDA approval.